QIAGEN expands QIAcuity digital PCR offering with over new 100 assays via GeneGlobe platform

Core Insights - QIAGEN has launched 100 new assays for its QIAcuity digital PCR platform, targeting applications in cancer research, genetic disorders, infectious disease surveillance, and environmental monitoring [1][2][3] - The company has exceeded its 2024 goal by launching over 130 new assays this year, contributing to a total of more than 2,300 validated assays [2] Product Development - The new assays include dPCR LNA Mutation and dPCR CNV Probe Assays, focusing on cancer-related mutations and copy number variations in genes associated with various cancers [3][4] - dPCR Microbial DNA Detection Assays are designed to identify pathogens linked to infectious diseases and antibiotic resistance, as well as animal and plant diseases [4] Market Adoption - QIAcuity digital PCR has seen strong adoption, with over 2,000 placements by the end of 2023 and citations in over 450 publications, serving key customers in pharmaceuticals, academia, and diagnostics [5] Technological Advancements - The QIAcuity platform utilizes nanoplates for sample partitioning, allowing simultaneous reading of reactions, which reduces processing time from six hours to two [6] - The platform is available in one-, four-, and eight-plate versions, catering to various laboratory sizes and throughput needs [6] Future Plans - An in-vitro diagnostic version of QIAcuity is set to launch in fall 2024, aimed at clinical applications such as diagnosing infectious diseases and monitoring cancer [7] - QIAGEN is collaborating with pharmaceutical companies to develop companion diagnostics using the QIAcuity platform [7]